Prothena Capex Per Share from 2010 to 2024

PRTA Stock  USD 14.53  0.75  5.44%   
Prothena Plc's Capex Per Share is decreasing over the years with stable fluctuation. Overall, Capex Per Share is expected to go to 0.09 this year. From 2010 to 2024 Prothena Plc Capex Per Share quarterly data regression line had arithmetic mean of  0.08 and r-squared of  0.03. View All Fundamentals
 
Capex Per Share  
First Reported
2010-12-31
Previous Quarter
0.05280367
Current Value
0.0855
Quarterly Volatility
0.11927773
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Prothena Plc financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Prothena Plc's main balance sheet or income statement drivers, such as Depreciation And Amortization of 881.6 K, Interest Expense of 8.1 M or Selling General Administrative of 34.6 M, as well as many indicators such as Price To Sales Ratio of 20.11, Dividend Yield of 0.0 or PTB Ratio of 3.62. Prothena financial statements analysis is a perfect complement when working with Prothena Plc Valuation or Volatility modules.
  
Check out the analysis of Prothena Plc Correlation against competitors.
For information on how to trade Prothena Stock refer to our How to Trade Prothena Stock guide.

Latest Prothena Plc's Capex Per Share Growth Pattern

Below is the plot of the Capex Per Share of Prothena plc over the last few years. It is Prothena Plc's Capex Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Prothena Plc's overall financial position and show how it may be relating to other accounts over time.
Capex Per Share10 Years Trend
Pretty Stable
   Capex Per Share   
       Timeline  

Prothena Capex Per Share Regression Statistics

Arithmetic Mean0.08
Geometric Mean0.04
Coefficient Of Variation152.54
Mean Deviation0.07
Median0.04
Standard Deviation0.12
Sample Variance0.01
Range0.4796
R-Value(0.18)
Mean Square Error0.01
R-Squared0.03
Significance0.52
Slope(0)
Total Sum of Squares0.20

Prothena Capex Per Share History

2024 0.0855
2023 0.0528
2022 0.009795
2021 0.013
2020 0.00491
2019 0.0139
2018 0.0447

About Prothena Plc Financial Statements

Prothena Plc stakeholders use historical fundamental indicators, such as Prothena Plc's Capex Per Share, to determine how well the company is positioned to perform in the future. Although Prothena Plc investors may analyze each financial statement separately, they are all interrelated. For example, changes in Prothena Plc's assets and liabilities are reflected in the revenues and expenses on Prothena Plc's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Prothena plc. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capex Per Share 0.05  0.09 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Prothena plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Prothena Plc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prothena Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prothena Plc Stock:
Check out the analysis of Prothena Plc Correlation against competitors.
For information on how to trade Prothena Stock refer to our How to Trade Prothena Stock guide.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prothena Plc. If investors know Prothena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prothena Plc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.46)
Revenue Per Share
2.482
Quarterly Revenue Growth
(0.99)
Return On Assets
(0.16)
Return On Equity
(0.23)
The market value of Prothena plc is measured differently than its book value, which is the value of Prothena that is recorded on the company's balance sheet. Investors also form their own opinion of Prothena Plc's value that differs from its market value or its book value, called intrinsic value, which is Prothena Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prothena Plc's market value can be influenced by many factors that don't directly affect Prothena Plc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prothena Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Prothena Plc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prothena Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.